← All trials
NCT06674226
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 15, 2024
- Primary completion
- Jun 30, 2026
- Completion date
- Jun 30, 2026
- First posted
- Nov 5, 2024
- Last posted
- Nov 5, 2024
- Enrollment
- 214
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Capital Medical UniversityLead sponsor
- Huazhong University of Science and TechnologyCollaborator
- Capital Medical UniversitySponsor investigator
- Nanjing UniversityCollaborator
- Nanchang UniversityCollaborator
- Central South UniversityCollaborator
- Central South UniversityCollaborator
- Capital Medical UniversityOfficial
- Hebei UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.